Two different goals, not two equivalent treatments

The comparison between ChondroFiller and corticosteroid injection is not a head-to-head contest between two equivalent options for the same problem. It is, at root, a question of what you need the treatment to do.

Corticosteroid works by suppressing the immune response within the knee joint, reducing inflammation, swelling, and pain. It does not address any structural cartilage loss; it manages the consequences of damage rather than the damage itself.

ChondroFiller is a Type I collagen scaffold placed into focal cartilage defects. Its mechanism — acellular matrix-induced chondrogenesis — is designed to recruit the body's own progenitor cells and support endogenous repair at the site of structural loss. The goal is cartilage preservation over time, not immediate pain suppression.

This distinction matters at the point of decision. Someone managing an acute inflammatory flare has different immediate priorities from someone with a focal defect on MRI who is trying to slow structural deterioration. Neither treatment is interchangeable with the other; in some situations, one may appropriately precede or work alongside the other on the treatment pathway. The right starting point is always the same question: is the priority symptom control now, or structural preservation over time?

Why focal cartilage defects need a deliberate treatment choice

Articular cartilage in the knee contains no blood vessels and no nerve supply. That structural fact carries a direct clinical consequence: once a defect forms, the tissue has almost no internal mechanism to repair itself. The body's standard injury response — bringing repair cells and growth factors via the bloodstream — simply cannot reach the joint surface in meaningful quantities.

This limited self-repair capacity explains why focal chondral defects are clinically significant even when they cause only intermittent symptoms. Large cohort studies of knee arthroscopy — one covering 25,124 procedures, another 31,516 — confirm how frequently these defects appear, often alongside meniscal or ligamentous injury. Without adequate treatment, defects above approximately 1 cm in diameter tend to expand over time, and accumulated damage can progress toward osteoarthritis, a condition affecting more than 10% of the population aged 60 or older.

For clinical decision-making, defect severity is categorised on the ICRS (International Cartilage Repair Society) scale from Grade 1 (surface softening) to Grade 4 (full-thickness loss reaching subchondral bone). Both ChondroFiller and corticosteroid injection are relevant for lower-grade focal defects; neither is appropriate where damage extends through the bone, at which point more involved reconstruction is typically required.

Accurate characterisation is therefore the necessary first step before any treatment choice is made. MRI is the diagnostic gold standard — advanced sequences including T2 mapping assess cartilage composition and defect depth in detail that plain X-ray cannot provide. AI-assisted MRI analysis, such as the cartilage segmentation and grading capability used in onMRI™, can add precision to this baseline assessment, helping clinicians determine whether a structural or symptom-focused approach is most appropriate.

How ChondroFiller works as an injectable collagen scaffold

ChondroFiller is a CE-marked Class III medical device — an acellular Type I collagen hydrogel that gels in situ once placed within the defect. The material is acid-extracted from Type I collagen, giving it high viscosity and rapid polymerisation properties that allow it to conform to the shape of the cartilage lesion and remain securely in position after injection.

The therapeutic mechanism is acellular matrix-induced chondrogenesis. Rather than delivering live cells, the scaffold creates a biological environment that draws the patient's own progenitor cells — from the synovium and subchondral bone — into the defect site. Those recruited cells can then support the body's own repair processes from within the collagen matrix. ChondroFiller does not regrow cartilage in any direct sense; it promotes endogenous repair by providing the structural scaffolding that an avascular cartilage defect cannot supply for itself.

For eligible patients with focal cartilage damage, treatment is delivered as an ultrasound-guided outpatient injection. The biological repair process takes time to establish: benefit accrues over weeks to months rather than the days associated with anti-inflammatory injections — a meaningful practical difference for anyone weighing the two options.

Published outcome series for ChondroFiller report an IKDC improvement of approximately 30 points, MOCART scores in the range of 70 to 87 (a validated imaging measure of cartilage repair fill and integration), and a complaint rate of approximately 0.06%. These figures reflect ChondroFiller's own clinical series rather than a direct comparative trial against corticosteroid, a distinction the decision framework in the following section addresses in full.

What corticosteroid does — and the cartilage risk that limits repeat use

Corticosteroid injection has a clear and legitimate role in knee pain management — one worth stating plainly before addressing its limitations. For patients in an acute inflammatory flare, or where severe joint swelling needs to be controlled before another procedure, a corticosteroid injection can reduce intra-articular inflammation quickly and meaningfully. These are the clinical scenarios in which the treatment is well placed.

The safety concern arises with repeated use, and it is specific to patients who already have cartilage loss. Research has shown that corticosteroids can stimulate matrix metalloproteinases — enzymes that degrade the structural proteins of cartilage — accelerating breakdown of tissue that is already under threat. Dragoo et al. (Knee Surg Sports Traumatol Arthrosc, 2012) identified chondrotoxic effects even at single-dose level; a subsequent systematic review by Wernecke, Braun, and Dragoo (Orthop J Sports Med, 2015) corroborated that finding across the available literature. The most clinically significant dataset is the McAlindon et al. RCT published in JAMA in 2017, which found measurable cartilage volume loss in patients receiving repeated triamcinolone injections compared with controls — providing direct imaging evidence of structural harm over time.

OARSI 2019 guidelines (Bannuru et al., Osteoarthritis and Cartilage) include corticosteroid as a recognised non-surgical treatment for knee osteoarthritis, while the field simultaneously acknowledges the unmet need for approaches that modify disease rather than mask symptoms. Corticosteroid is a short-term symptomatic tool, not a structural solution — a distinction that changes weight considerably when cartilage loss is the underlying diagnosis rather than isolated inflammation.

The decision framework: six axes that point toward the right choice

Six practical axes structure the choice between these two injections. No head-to-head randomised trial comparing them specifically for focal knee cartilage defects has yet been published, so the framework below draws on the mechanistic and clinical evidence for each intervention separately — which is the honest basis on which most clinical decisions in this area are currently made.

Axis 1 — Treatment goal

ChondroFiller provides a regenerative scaffold, promoting endogenous repair from within the defect through acellular matrix-induced chondrogenesis. Corticosteroid targets the inflammatory response and symptom load; it does not address underlying structural tissue loss.

Axis 2 — Defect type

ChondroFiller is indicated for confirmed focal chondral defects. Corticosteroid suits acute inflammatory flares, but carries escalating risk in joints where cartilage is already structurally compromised.

Axis 3 — Speed of effect

ChondroFiller's regenerative benefit builds over weeks to months as the scaffold is integrated and endogenous repair progresses. Corticosteroid acts more rapidly — relevant where symptom control ahead of another intervention, or during a severe flare, is the immediate clinical priority.

Axis 4 — Safety with repetition

Repeated corticosteroid use carries documented chondrotoxicity risk, detailed in the previous section. ChondroFiller does not share that degradative profile, though its long-term evidence base continues to develop.

Axis 5 — Procedural setting and preparation

Both are delivered as intra-articular injections. ChondroFiller requires more complex preparation and precise placement than a standard corticosteroid injection; clinical assessment is needed to confirm suitability and setting.

Axis 6 — Escalation and combination potential

The two injections are not mutually exclusive. Corticosteroid may be used first to settle an acute inflammatory episode, with ChondroFiller considered subsequently for structural repair once the acute phase has resolved. Defect size and grade, age, activity level, and overall joint condition all determine whether one, both sequentially, or neither is appropriate — and that determination requires individual clinical assessment rather than a fixed protocol.

Getting a proper assessment at Lincolnshire Knee

The decision framework in the preceding section can clarify thinking, but it cannot substitute for the one piece of information the framework actually requires: accurate characterisation of the defect itself. Defect size, ICRS grade, the condition of surrounding cartilage, and the integrity of the subchondral bone all alter the calculation — and that information comes from imaging and clinical examination, not symptom history alone. A patient choosing between ChondroFiller and corticosteroid without a confirmed defect profile is choosing without the relevant data.

At Lincolnshire Knee, consultant-led assessment is available at Sleaford (NG34) and Grantham (NG31) without requiring a GP referral. The Sleaford Regeneration Hub provides advanced MRI capability including onMRI™ AI-driven cartilage and meniscus analysis with T2 mapping — the structural detail that distinguishes a focal Grade II lesion from a Grade III–IV defect and changes the treatment decision accordingly. Where loading patterns are relevant to how a defect is progressing, MAI Motion® objective gait analysis adds biomechanical context that clinical examination alone may not capture.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral. Book an assessment at lincolnshireknee.co.uk.

1. [1] Articular cartilage repair — Wikipedia. https://en.wikipedia.org/?curid=19042351 https://en.wikipedia.org/?curid=19042351